

Cerep enters into a significant profiling and BioPrint® database agreement with Lilly

Rueil-Malmaison, France, February 18, 2003 - press release 2003/04

Cerep today announces the signature of a major scientific agreement with Eli Lilly and Company for profiling* and BioPrint® related information.

Under the terms of the agreement, Lilly and Cerep will undertake an intensive profiling project to define the chemical space that is most suitable for use in discovering lead compounds active against important target classes. As part of the collaboration, Lilly will gain access to selected parts of Cerep's proprietary BioPrint® database. Financial terms are not disclosed.

Lilly will utilize Cerep's extensive experience in high throughput compound profiling and aspects of Cerep's proprietary BioPrint® database to enhance the fundamental understanding of the relationships between chemical structure and biological activity.

"We are very proud of the recognition by Lilly of the value of our profiling expertise and the related BioPrint® database in bringing fundamental advances to drug discovery", commented Thierry Jean, Chairman and CEO of Cerep. "This collaboration supports the application of large scale profiling, pioneered by Cerep, as a key technology for potential early generation of lead compounds."

** Determination of the biological effects of chemical entities on several targets of pharmaceutical interest.*

Cerep's mission is to build a pipeline of drug candidates aimed to be licensed out at the beginning of clinical phases. The drug discovery effort is financed through profitable fee for service activities.

Cerep provides solutions allowing faster and cost effective drug discovery by identifying at early stages the most promising drug candidates as well as eliminating those compounds likely to fail in development. Cerep's integrated platform encompasses a complete range of technologies including chemistry, biology, and informatics.

Cerep's technologies benefit to more than 200 pharmaceutical and biotechnological companies worldwide including most of the top pharmaceutical firms.

Cerep's drug pipeline includes collaborative drug candidates developed with Bristol-Myers Squibb, Sanofi-Synthélabo and Sepracor, as well as products discovered on its own.

Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights and other factors described in the company's Document de référence.

Contact

Thierry Jean, President and CEO

Tel. +33 (0)1 55 94 84 00

fincom@cerep.fr

Code Euroclear France : 6179 – Nouveau Marché